Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY – Get Free Report)’s share price hit a new 52-week high during trading on Wednesday . The company traded as high as $13.8475 and last traded at $13.4450, with a volume of 502 shares traded. The stock had previously closed at $13.23.
Wall Street Analyst Weigh In
Separately, Zacks Research upgraded shares of Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold”.
Get Our Latest Stock Report on SNPHY
Santen Pharmaceutical Stock Performance
About Santen Pharmaceutical
Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.
With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.
Further Reading
- Five stocks we like better than Santen Pharmaceutical
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Santen Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santen Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
